×
About 98 results

ALLMedicine™ Acute Angioedema Center

Research & Reviews  30 results

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
https://clinicaltrials.gov/ct2/show/NCT03485911

Mar 3rd, 2022 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Angioedema: differential diagnosis and acute management.
https://doi.org/10.1080/00325481.2021.1945219
Postgraduate Medicine; Tachdjian R, Johnston DT

Jun 18th, 2021 - A clinical vignette illustrates a typical presentation of a patient seeking help for acute angioedema. Despite the risks of SARS-CoV-2 (COVID-19) exposure, it is critical to evaluate patients with acute angioedema in person, because there is alway...

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02741596

Jun 8th, 2021 - This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
https://clinicaltrials.gov/ct2/show/NCT01095510

Jun 3rd, 2021 - Each subject received CINRYZE for treatment of a single acute angioedema attack.

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02586805

Jun 2nd, 2021 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

see more →

Clinicaltrials.gov  7 results

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
https://clinicaltrials.gov/ct2/show/NCT03485911

Mar 3rd, 2022 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02741596

Jun 8th, 2021 - This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
https://clinicaltrials.gov/ct2/show/NCT01095510

Jun 3rd, 2021 - Each subject received CINRYZE for treatment of a single acute angioedema attack.

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
https://clinicaltrials.gov/ct2/show/NCT02586805

Jun 2nd, 2021 - This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan
https://clinicaltrials.gov/ct2/show/NCT03873116

Mar 4th, 2021 - This is a phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE who live in Japan.

see more →

News  2 results

FDA approves C1-esterase inhibitor for hereditary angioedema
https://www.mdedge.com/chestphysician/article/85840/dermatology/fda-approves-c1-esterase-inhibitor-hereditary-angioedema
Elizabeth Mechcatie, MDedge News

Jul 17th, 2014 - Ruconest, an injectable human recombinant C1-esterase inhibitor, has been approved by the Food and Drug Administration for treating acute angioedema attacks in adults and adolescents with hereditary angioedema. Ruconest is the first recombinant C1.

Study Finds Icatibant Relieves Acute Angioedema
https://www.mdedge.com/internalmedicine/article/33680/dermatology/study-finds-icatibant-relieves-acute-angioedema
Sherry Boschert

Apr 8th, 2011 - SAN FRANCISCO – The experimental drug icatibant relieved moderate or severe acute attacks of hereditary angioedema faster than placebo in the third randomized, double-blind, controlled trial of the experimental drug in 98 patients. Among 88 patien.

see more →